Mihaela Minea | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Mihaela Minea β€” Ovidius University of ConstanΘ›a
Mihaela Minea
Affiliation Ovidius University of ConstanΘ›a
Country Romania
Scopus ID 58509570100
Documents 65
Citations 67
h-index 4
Subject Area Personalized Medicine
Event International Top Pharmaceutical Awards

Mihaela Minea is associated with Ovidius University of ConstanΘ›a, Romania, and has contributed to the interdisciplinary field of personalized medicine, rehabilitation sciences, and clinical evaluation methodologies. Her academic profile reflects scholarly engagement in rehabilitation assessment, gait analysis, and evidence-based healthcare approaches relevant to modern pharmaceutical and therapeutic research practices.[1] Her publication activity and citation profile demonstrate continuing participation in applied medical research with emphasis on patient-centered clinical outcomes and rehabilitation innovation.[2]

Abstract

This academic recognition article presents an overview of the scholarly profile and research contributions of Mihaela Minea in the domain of personalized medicine and rehabilitation sciences. Her work includes research on computerized gait analysis, rehabilitation outcomes, and clinical assessment methodologies. The research profile demonstrates involvement in interdisciplinary healthcare research integrating rehabilitation sciences with evidence-based medical evaluation frameworks. The publication record and citation activity indicate continuing academic participation in applied medical and pharmaceutical research relevant to patient-centered healthcare advancement.[1][3]

Keywords

Personalized Medicine, Rehabilitation Sciences, Clinical Research, Gait Analysis, Evidence-Based Medicine, Pharmaceutical Research, Osteoarthritis Rehabilitation, Healthcare Innovation, Medical Assessment, Research Evaluation

Introduction

Personalized medicine has become an important area within modern healthcare systems due to its focus on individualized therapeutic strategies, rehabilitation optimization, and patient-centered clinical interventions. Researchers working in this field contribute to the development of assessment methodologies that improve rehabilitation outcomes and evidence-based healthcare decision-making. Mihaela Minea has participated in research activities related to rehabilitation analysis and clinical outcome assessment, particularly within gait evaluation and osteoarthritis rehabilitation studies.[2] Such investigations support broader advancements in clinical rehabilitation sciences and therapeutic monitoring systems relevant to pharmaceutical and healthcare applications.[4]

Research Profile

The research profile of Mihaela Minea includes scholarly contributions indexed within Scopus author databases and related scientific platforms. Her documented academic activities involve publications associated with rehabilitation medicine, gait analysis technologies, and clinical healthcare evaluation systems.[1] The available citation metrics indicate an active contribution to interdisciplinary medical research with recognized engagement in healthcare-oriented investigations. The combination of publication records, citation activity, and subject specialization demonstrates sustained involvement in patient-focused rehabilitation studies and evidence-driven clinical methodologies.[5]

Research Contributions

The documented research contributions of Mihaela Minea include involvement in studies examining rehabilitation outcomes and computerized gait analysis systems for patients affected by knee osteoarthritis. These studies contribute to the understanding of rehabilitation effectiveness and objective clinical evaluation approaches in musculoskeletal healthcare management.[2] Research activities in rehabilitation sciences are increasingly relevant for modern healthcare systems because they support therapeutic optimization, monitoring strategies, and individualized rehabilitation planning. The integration of digital analysis tools into rehabilitation research also reflects broader trends in precision medicine and data-informed healthcare delivery.[6]

Publications

Selected scientific publications associated with Mihaela Minea demonstrate research interest in rehabilitation science, clinical assessment methodologies, and gait analysis applications in osteoarthritis rehabilitation.[2] These publications contribute to the broader scientific understanding of rehabilitation monitoring and healthcare evaluation systems relevant to personalized therapeutic approaches.[3]

Research Impact

Research impact within rehabilitation sciences is often evaluated through publication indexing, citation activity, and interdisciplinary relevance. The available citation record associated with Mihaela Minea indicates academic recognition within clinical and rehabilitation research communities.[1] Her scholarly work contributes to evidence-based rehabilitation practices and supports continuing discussions regarding digital clinical assessment technologies and patient-centered rehabilitation models. Such contributions are relevant to healthcare professionals, rehabilitation specialists, and medical researchers interested in outcome-oriented therapeutic evaluation systems.[4]

Award Suitability

Mihaela Minea demonstrates suitability for recognition through the Best Researcher Award based on her documented academic contributions, indexed research profile, and participation in rehabilitation and personalized medicine studies. Her scholarly activities align with the objectives of the International Top Pharmaceutical Awards, which recognize meaningful scientific engagement and interdisciplinary healthcare research contributions.[5] The combination of research activity, publication records, and citation visibility supports recognition within professional academic and clinical research environments. Her contributions further reflect continuing efforts toward evidence-based rehabilitation assessment and healthcare innovation.[6]

Conclusion

Mihaela Minea has contributed to the advancement of rehabilitation sciences and personalized medicine through scholarly participation in gait analysis and clinical rehabilitation research. Her academic profile reflects interdisciplinary engagement in evidence-based healthcare methodologies and rehabilitation assessment systems. The indexed research record, citation activity, and continuing relevance of her scientific work support recognition within professional medical and pharmaceutical research communities. These contributions remain relevant to contemporary discussions surrounding patient-centered healthcare, rehabilitation optimization, and digital clinical evaluation technologies.[1][3]

References

  1. Elsevier. (n.d.). Scopus author details: Mihaela Minea, Author ID 58509570100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58509570100
  2. Minea, M., et al. (2023). Using Computerised Gait Analysis to Assess Changes After Rehabilitation in Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Gait Speed Improvement. Healthcare.DOI: https://doi.org/10.3390/healthcare11050639

Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab β€” Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Walter Manucha | Nanopharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Walter Manucha
National Scientific and Technical Research Council, Argentina
Walter Manucha
Affiliation National Scientific and Technical Research Council
Country Argentina
Scopus ID 57195218813
Documents 2665
Citations 3316
h-index 34
Subject Area Nanopharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-2279-7626

Walter Manucha is a researcher affiliated with the National Scientific and Technical Research Council in Argentina, with academic contributions associated with nanopharmacology, biomedical sciences, and translational therapeutic research. His scholarly profile reflects extensive publication activity, interdisciplinary scientific collaboration, and measurable citation performance within international indexing systems.[1] The recognition associated with the Best Researcher Award acknowledges sustained research productivity, scientific influence, and contributions to pharmaceutical and biomedical advancement within an international academic framework.[2]

Abstract

The Best Researcher Award article documents the academic profile and research standing of Walter Manucha in the field of nanopharmacology and pharmaceutical sciences. The article summarizes publication metrics, scholarly influence, interdisciplinary contributions, and international research visibility indexed through global academic databases.[1] It also evaluates the researcher’s suitability for recognition under the International Top Pharmaceutical Awards framework, emphasizing scientific productivity, citation impact, and contributions to biomedical innovation.[2]

Keywords

Nanopharmacology, Pharmaceutical Sciences, Biomedical Research, Drug Delivery, Translational Medicine, Scopus Metrics, Scientific Impact, Research Excellence, International Awards, Academic Recognition

Introduction

Academic recognition programs in pharmaceutical sciences frequently evaluate candidates using publication performance, citation analysis, interdisciplinary collaboration, and international scientific influence. Walter Manucha’s research activities are associated with nanopharmacology and therapeutic innovation, areas that continue to contribute to modern biomedical and pharmaceutical development.[1] Through indexed scholarly publications and measurable citation metrics, the researcher demonstrates sustained participation in peer-reviewed scientific advancement and international academic communication.[3]

Research Profile

Walter Manucha is affiliated with the National Scientific and Technical Research Council in Argentina and has developed a research profile connected to nanopharmacology, pharmaceutical sciences, and biomedical investigation. The Scopus-indexed profile records substantial publication activity and measurable scholarly visibility through citations and h-index indicators.[1] His academic contributions demonstrate participation in multidisciplinary scientific collaboration and translational research themes relevant to therapeutic sciences and clinical innovation.[4]

  • Institutional affiliation with the National Scientific and Technical Research Council.
  • Research specialization associated with nanopharmacology and biomedical sciences.
  • Scopus-indexed publication and citation visibility.
  • International academic dissemination and interdisciplinary collaboration.

Research Contributions

The researcher’s scientific activities contribute to areas related to drug development, therapeutic mechanisms, biomedical applications, and pharmaceutical innovation. Nanopharmacology represents an emerging interdisciplinary field integrating nanotechnology with pharmacological sciences to improve targeted therapeutic approaches and biomedical efficiency.[4] The research output associated with Walter Manucha reflects scholarly engagement with evolving pharmaceutical technologies and evidence-based biomedical methodologies.[5]

  • Development of interdisciplinary biomedical research frameworks.
  • Contributions to therapeutic and pharmaceutical sciences.
  • Scientific dissemination through indexed journal publications.
  • Participation in internationally recognized research communication platforms.

Publications

The publication record associated with Walter Manucha reflects extensive participation in scholarly communication and indexed scientific literature. Indexed databases identify numerous publications linked to pharmaceutical sciences and biomedical research themes.[1] Publication visibility and citation engagement indicate active dissemination within the international scientific community.[3]

  1. Research articles in nanopharmacology and biomedical sciences.
  2. Peer-reviewed publications indexed in international databases.
  3. Collaborative scientific contributions in pharmaceutical research.
  4. Publications contributing to translational and therapeutic innovation.

Research Impact

Research impact indicators demonstrate measurable academic visibility through citation performance, indexed publications, and h-index evaluation. Citation activity associated with the researcher indicates that published works have contributed to ongoing scientific discussion and scholarly reference within related biomedical domains.[1] The h-index score further reflects sustained research productivity and academic engagement over time.[3]

  • Scopus-indexed visibility and citation accumulation.
  • Sustained publication activity within pharmaceutical sciences.
  • Research dissemination through international scholarly networks.
  • Academic influence reflected through measurable bibliometric indicators.

Award Suitability

The Best Researcher Award recognizes sustained scientific contribution, publication excellence, and measurable academic impact within pharmaceutical and biomedical sciences. Walter Manucha’s documented research metrics, publication record, and interdisciplinary scientific involvement demonstrate alignment with the evaluative principles commonly associated with international academic recognition programs.[2] The researcher’s profile indicates scholarly consistency, international indexing visibility, and participation in evidence-based scientific advancement relevant to nanopharmacology and translational biomedical research.[5]

Conclusion

Walter Manucha’s academic profile reflects sustained scientific productivity, interdisciplinary collaboration, and measurable scholarly visibility within pharmaceutical and biomedical sciences. Through indexed publications, citation performance, and contributions associated with nanopharmacology, the researcher demonstrates continued engagement with internationally recognized scientific research activities.[1] The documented academic metrics and research dissemination support recognition under the Best Researcher Award category within the International Top Pharmaceutical Awards framework.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Walter Manucha, Author ID 57195218813. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57195218813
  2. International Top Pharmaceutical Awards. (n.d.). Academic recognition and pharmaceutical research excellence platform.
    https://toppharmaceutical.org/
  3. MartΓ­n Gimenez, V. M., GarcΓ­a Menendez, S., & Manucha, W. (2026). Multi-endogenous nanoformulation for endocannabinoid and hormonal modulation of key signaling pathways in resistant hypertension. Current Pharmaceutical Design.
    https://doi.org/10.2174/0113816128396666250728074858
  4. Reiter, R. J., Sharma, R., Loh, D., Chuffa, L. G. A., Bai, Y., Zuccari, D. A. P. C., Galano, A., & Manucha, W. (2026). Melatonin targets mitochondrial redox homeostasis: Optimizing the intracellular microenvironment. International Journal of Molecular Sciences.
    https://doi.org/10.3390/ijms27104496
  5. Carloni, S., Luchetti, F., Nasoni, M. G., Balduini, W., Manucha, W., & Reiter, R. J. (2026). Melatonin and mitochondrial stress: New insights into age-related neurodegeneration. Neural Regeneration Research.
    https://doi.org/10.4103/NRR.NRR-D-24-01380

Kelly Yoo | Precision Medicine | Best Scholar Award

Published on by Top Pharmaceutical

Dr. Kelly Yoo | Precision Medicine | Best Scholar Award

Kelly Yoo at Stanford University | United States

Dr. Kelly H. Yoo is a physician-scientist specializing in neurosurgery and neuro-oncology, currently conducting postdoctoral research at Stanford University. Her work bridges translational neuroscience, radiosurgery, and artificial intelligence in clinical applications. She has authored numerous peer-reviewed articles and case studies on stereotactic radiosurgery, spinal disorders, and brain metastases. Dr. Yoo has received multiple international awards and fellowships for her academic excellence and research leadership. As a committed member of professional organizations and advisory boards, she contributes to global health, clinical innovation, and medical education. Her research efforts aim to improve patient outcomes through technology-enhanced, precision-targeted therapies.

Publication ProfileΒ 

Scopus

EducationΒ 

Dr. Kelly Yoo earned her International Baccalaureate Diploma and graduated. She later obtained her MD with top distinction and completed her Doctorate (Dr. med., magna cum laude) from Heidelberg University School of Medicine. Her academic path included rigorous clinical, research, and methodological training. She completed multiple advanced certifications, including GCP, IRB, and Clinical Trial Investigator courses. She studied Fundamental Neuroscience for Neuroimaging at Johns Hopkins University and holds licenses and fellowships from institutions in Germany and the U.S., further enhancing her global medical and scientific competency.

ExperienceΒ 

Dr. Yoo currently serves as a postdoctoral fellow at Stanford University, focusing on clinical and translational research in neurosurgery. She completed a clinician-scientist residency track in Baden-WΓΌrttemberg and has worked across Europe and North America in academic medical centers. She is active in multiple professional societies, including AANS, CNS, and EANO. Dr. Yoo has held leadership roles in Stanford’s postdoc community and initiated several mentorship and international programs. Her academic career includes significant contributions to radiosurgical research and spinal navigation, leveraging both clinical experience and data-driven methodologies to explore innovative therapeutic solutions.

Awards and HonorsΒ 

Dr. Kelly Yoo has received numerous prestigious accolades, including the SPARK at Stanford Grant Award, Wu Tsai Neurosciences Interdisciplinary Fellowship, and multiple scholarships from the German Academic International Network (GAIN). She was also awarded the E-Fellows Gifted Education Scholarship and earned top academic distinctions from Heidelberg University and the International Baccalaureate program. She has consistently ranked in the top percentile across educational stages and received first-place honors in international mathematics competitions. Her recognitions reflect a long-standing commitment to academic excellence, scientific innovation, and leadership in neuroscience, medicine, and global health initiatives.

Research FocusΒ 

Dr. Yoo’s research primarily centers on stereotactic radiosurgery, neuro-oncology, spinal disorders, and the integration of AI and neuroimaging into surgical planning and treatment. She investigates the clinical applications of advanced radiological techniques in treating recurrent and metastatic brain and spinal tumors. Her recent work explores synergistic effects between radiosurgery and immunotherapy and the cost-effectiveness of neurosurgical interventions. She also contributes to studies on spinal navigation, robotic-assisted surgery, and PET/MRI-guided interventions. Her interdisciplinary focus aims to enhance precision medicine and outcome prediction models in neurosurgery by blending clinical insight with computational innovation.

Publication Top Notes

Suspected and surgically managed cauda equina syndrome nationwide: epidemiological trends and socioeconomic factors influencing access to care

Trends in Sacroiliac Joint Fusion Costs and Utilization in the Privately Insured Population

Mario Leporace | Personalized Medicine | Best Innovation Award

Published on by Top Pharmaceutical

Mario Leporace | Personalized Medicine | Best Innovation Award

Prof. Dr. Mario Leporace, Hospital and University, Italy

Prof. Dr. Mario Leporace is a distinguished Clinical Radiologist at the Department of Nuclear Medicine and Theragnostics, β€œMariano Santo” Hospital, Cosenza, Italy. With expertise in oncologic imaging, hybrid and molecular imaging, and cardiovascular radiology, he is renowned for his advanced diagnostic work using X-ray, CT, MRI, PET/CT, and SPECT/CT. He holds a Master’s in Interventional Oncology and has contributed to over 15 peer-reviewed publications. His professional journey spans top institutions in Rome and Cosenza, marking a career dedicated to innovation in radiology and nuclear medicine.

Publication Profile

Scopus

Education

Prof. Dr. Mario Leporace πŸŽ“ is a distinguished expert in interventional oncology and radiology. In 2022, he earned a Master’s Degree in Interventional Oncology from Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, with a thesis on thermal ablation of bone metastases πŸ”₯🦴. From 2001 to 2005, he completed his post-graduate certification in Radiology at the University of Rome β€œTor Vergata” πŸ₯, graduating cum laude with a thesis on hybrid imaging πŸ§ πŸ“Έ. He also obtained his Degree in Medicine and Surgery from the same university (1995–2001), graduating with top honors and a thesis in vascular imaging πŸ«€πŸ§¬.

Experience

Prof. Dr. Mario Leporace 🩺 has an extensive career in radiology and nuclear medicine, showcasing over two decades of dedicated medical service. Since October 2017, he has been serving in the Department of Nuclear Medicine and Theragnostics at β€œMariano Santo” Hospital in Cosenza, Italy βš›οΈπŸ₯. From May 2016 to September 2017, he worked at the Department of Radiology, β€œAnnunziata” Hospital 🏨. Earlier, from March 2006 to April 2016, he contributed to the European Hospital in Rome, and concurrently, from November 2005 to April 2016, served at the Aurelia Hospital in Rome πŸ›οΈπŸ”¬, strengthening his clinical expertise across institutions.

Research Focus

Prof. Dr. Mario Leporace focuses his research on Thermal Ablation with Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) πŸ”¬πŸ§ . His work bridges medical physics and oncological applications, exploring non-invasive treatments that use focused ultrasound energy to thermally ablate tumors with MRI precision guidance 🎯. This technique offers cutting-edge therapeutic possibilities in fields such as oncology, neurology, and women’s health πŸ§¬πŸ’‘. Prof. Leporace’s contributions advance both the clinical outcomes and technological innovation of MRgFUS, making him a key figure in image-guided therapy, minimally invasive surgery, and cancer treatment research .

Publication Top Notes

The Thermal Ablation with MRgFUS: From Physics to Oncological Applications

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Prof. Zhi-Ming Shao, Fudan University Shanghai Cancer Center, China

Prof. Zhi-Ming Shao is a distinguished surgical oncologist and global leader in breast cancer research. A graduate of Shanghai Medical University, he chairs the Department of Breast Surgery at Fudan University Shanghai Cancer Center and directs its Breast Cancer Institute. With extensive postdoctoral experience in the U.S. and over 30 years of academic excellence, Prof. Shao has received numerous national honors, including the Chang Jiang Scholar and China’s Most Beautiful Doctor Award. His groundbreaking research, published in top journals like Nature Genetics and Cancer Cell, has significantly advanced precision oncology and breast cancer therapy worldwide.

Publication Profile

Scopus

Education

Prof. Zhi-Ming Shao began his medical journey at Shanghai Medical University, where he earned his Bachelor of Medicine (1980–1985). Driven by a passion for cancer treatment, he pursued a Residency in Surgical Oncology (1985–1990) at the prestigious Fudan University Shanghai Cancer Center. During this period, he also completed his Doctor of Medicine (M.D.) through a Postgraduate Course in Surgical Oncology (1987–1990) at Shanghai Medical University. His comprehensive education laid a strong foundation for his distinguished career in oncology, combining clinical expertise with academic excellence.

Experience

Prof. Zhi-Ming Shao has undergone extensive professional training and leadership roles in oncology. He began as a Postdoctoral Research Fellow (1990–1991) at Wake Forest University, followed by a role as Research Associate (1991–1995) at the University of Maryland Cancer Center. Returning to China, he became Associate Professor (1996–1998) and then Professor (1998–present) at Fudan University Shanghai Cancer Center. Since 2000, he has chaired the Department of Breast Surgery and became Director of the Breast Cancer Institute (2019–present). He also served as Chairman of the 8th Asian Breast Cancer Association (2010–2012) and is now Honorary Chairman of the China Anti-Cancer Association.

Awards

Prof. Zhi-Ming Shao has received numerous prestigious honors and awards throughout his career. In 1998, he was named one of the first batch of distinguished professors of the Chang Jiang Scholars Program. He was awarded the National Science Fund for Distinguished Young Scholars in 2001 and recognized as a Young and Middle-aged Expert with Outstanding Contributions by the Ministry of Health of China in 2004. His accomplishments include the National Prize of Science and Technology Progress (Grade II) in 2005, the National May Day Labor Medal in 2008, and the Chinese Physician Prize in 2020. He was also honored with the 2023 China’s Most Beautiful Doctor Award.

Research Focus

Prof. Zhi-Ming Shao’s research focuses on breast cancer, particularly in the areas of pathogenesis and treatment strategies. His work explores novel therapeutic approaches, such as targeting specific pathways involved in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, as well as developing targeted imaging agents for improved diagnosis. Prof. Shao has contributed significantly to understanding the molecular mechanisms of breast cancer progression and therapy resistance. His studies involve investigating genetic markers, tumor microenvironment interactions, and new treatment combinations. Overall, his research aims to improve clinical outcomes for breast cancer patients, especially in advanced or resistant cases.

Publication Top Notes

Breast cancer: pathogenesis and treatments

Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4

LINC01235 Promotes Clonal Evolution through DNA Replication Licensing-Induced Chromosomal Instability in Breast Cancer

Pilot Study of Nectin-4–Targeted PET Imaging AgentΒ 68Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human

Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial

The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer

O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-Ξ² signaling to breast cancer progression

Symptoms Related to Brachial Plexus Neuropathy After Supraclavicular Irradiation and Boost in Breast Cancer

Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapy

TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Assist. Prof. Dr. KYU SHIK MUN, Cedars-Sinai Medical Center, United States

Assist. Prof. Dr. Kyu Shik Mun is a distinguished researcher in cystic fibrosis (CF) and biomedical engineering 🧬. As a Principal Investigator and Co-Director, he has led groundbreaking projects on CF-related diabetes, organ-on-a-chip models, and personalized CF therapy πŸ₯. His work, funded by organizations like the Cystic Fibrosis Foundation and Vertex Pharmaceuticals, has yielded significant patents and high-impact publications πŸ“‘. With 733 citations, an h-index of 10, and an i10-index of 10, Dr. Mun continues to drive innovations in CF research, bridging biomedical science and translational medicine πŸ”¬.

Publication Profile

Google Scholar

Professional Background

Assist. Prof. Dr. Kyu Shik Mun earned his Ph.D. in the Materials Science and Engineering Program at the University of Cincinnati πŸŽ“. In 2016, he joined the Cystic Fibrosis Research Center at Cincinnati Children’s Hospital, where he pioneered a microfluidic-based organ-on-chip program from scratch πŸ₯🧬. His groundbreaking research focused on studying cystic fibrosis and related disorders. In 2021, he was promoted to Assistant Professor at Cedars-Sinai πŸ†, where he continues to advance in vitro cell culture models using organ-on-chip technology and 3D bioprinting πŸ–¨οΈπŸ”¬, contributing to innovative solutions in biomedical research and personalized medicine.

Awards

Assist. Prof. Dr. Kyu Shik Mun has received numerous prestigious honors and awards throughout his academic and professional journey πŸŽ–οΈ. He was awarded multiple Outstanding Grade Scholarships at Gangneung National University πŸ… (2000–2009) and recognized for excellence with department and presidential awards πŸ†. His achievements include a scholarship from the Korean Broadcasting System πŸ“Ί and the Korea Research Foundation 🌏. During his Ph.D. at the University of Cincinnati, he earned a University Graduate Scholarship πŸŽ“ (2010–2014). His research has been recognized by the American Gastroenterological Association and the Cystic Fibrosis Foundation 🧬, receiving multiple Best Abstract and Early Career Investigator awards (2017–2024) πŸ₯‡.

ExperienceΒ 

Assist. Prof. Dr. Kyu Shik Mun has been actively involved in non-clinical teaching, contributing to journal clubs and lab mentoring πŸ“šπŸŽ€. He has delivered key presentations on organ-on-a-chip technology 🧬, including talks at Cincinnati Children’s Hospital (2020) and Cedars-Sinai (2021) πŸ₯. His mentorship spans postdoctoral fellows, research associates, and Ph.D. students, guiding projects in 3D bioprinting πŸ–¨οΈ and patient-derived lung-on-a-chip models 🌬️. Since 2016, he has mentored 15 summer and rotation studentsβ€”including high school, college, Ph.D., and MD candidatesβ€”on fabricating organ-on-a-chips and culturing cells, fostering the next generation of biomedical researchers πŸ”¬.

Research Focus

Assist. Prof. Dr. Kyu Shik Mun’s research primarily focuses on nanotechnology πŸ§ͺ, biosensors 🧫, and biomedical engineering πŸ₯. His work spans optical interferometric biosensors for label-free detection, organ-on-a-chip models for diseases like cystic fibrosis 🫁, and TiOβ‚‚ nanotube arrays for applications in solar cells β˜€οΈ and photocatalysis. He also explores drug discovery πŸ’Š by targeting molecular pathways in cystic fibrosis and related disorders. His interdisciplinary research integrates materials science πŸ—οΈ, biophysics βš›οΈ, and microfluidics πŸ”¬ to develop innovative medical technologies, aiming to advance precision medicine 🎯 and renewable energy solutions 🌱.

Publication Top Notes

A Stable, Label-free Optical Interferometric Biosensor Based on TiO2Β Nanotube Arrays

Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders

Guided construction of single cell reference for human and mouse lung

Targeting the pregnane X receptor using microbial metabolite mimicry

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations

Surface passivation of highly ordered TiO2 nanotube arrays and application to dye-sensitized solar cells using the concept of isoelectric point

Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue Ξ”F508-CFTR

Guanylate cyclase 2C agonism corrects CFTR mutants

Cystic Fibrosis Human Organs-on-a-Chip

Nibras Mohammed Sahi | Drug Delivery Systems | Women Researcher Award

Published on by Top Pharmaceutical

Nibras Mohammed Sahi | Drug Delivery Systems | Women Researcher Award

Assist. Prof. Dr. Nibras Mohammed Sahi, Ministry of Higher Education and Scientific Research, University of Babylon, Iraq

Dr. Nebras Mohammed Sahi πŸ¦‹, an Assistant Professor at the University of Babylon, specializes in entomology and plant extracts 🌿. Her research explores insect-derived products and medicinal plant applications in anticancer and antibacterial treatments πŸ§ͺ. She has contributed to high-impact journals πŸ“„ indexed in SCI and Scopus. Dr. Sahi prepared the propolis and Alhagi maurorum extract used in her latest research. Her work advances medicine, agriculture, and sustainability 🌍. With a citation index of 3, she actively collaborates on innovative biological studies. πŸ’‘πŸ”¬

Publication Profile

orcid

Professional Background

Dr. Nibras Mohammed Sahi πŸ¦‹, an Assistant Professor, specializes in entomology and plant extracts, focusing on the study of insects and their beneficial products. Her research explores the diverse applications of insect-derived compounds in medicine πŸ’Š, agriculture 🌱, and sustainability 🌍. Through collaborations with universities and research institutions, she investigates innovative ways to harness the potential of insects for ecological and economic benefits. Driven by a passion for scientific discovery πŸ”¬, Dr. Sahi’s work contributes to advancements in bio-based solutions, aiming to enhance environmental conservation and agricultural productivity while promoting sustainable development.

Ongoing Research

Dr. Nibras Mohammed Sahi πŸ¦‹ is actively engaged in research on insect-derived products and plant extracts, with a particular focus on propolis 🐝 and Alhagi maurorum 🌿 for cancer 🧬 and antibacterial 🦠 applications. Her studies explore the therapeutic potential of these natural compounds, aiming to develop innovative solutions in medicine πŸ’Š and biotechnology. While her work aligns with prestigious award categories, highlighting specific project funding πŸ’°, collaborations 🀝, or research grants would further strengthen her academic profile. Through her dedication to scientific discovery πŸ”¬, Dr. Sahi contributes to advancements in natural product research and sustainable healthcare solutions.

Professional Memberships

Dr. Nibras Mohammed Sahi πŸ¦‹ has not listed any editorial appointments, active collaborations, or professional memberships. However, participation in scientific societies πŸ›οΈ, international conferences 🎀, or editorial boards πŸ“‘ would significantly enhance her academic profile. Engaging in peer-reviewed journals πŸ“š, contributing to scientific committees πŸ…, or collaborating on global research initiatives 🌍 would further establish her influence in the field of entomology and natural product research. Highlighting such professional engagements would strengthen her candidacy, showcasing her dedication to advancing scientific knowledge πŸ”¬ and fostering collaborations that drive innovation in medicine πŸ’Š, agriculture 🌱, and sustainability 🌿.

Research Focus

Assist. Prof. Dr. Nibras Mohammed Sahi’s research primarily focuses on microbiology 🦠, antibiotic resistance πŸ’Š, and bioactive compounds 🌱. His studies encompass pathogenic bacteria identification 🧫, antimicrobial activity testing πŸ§ͺ, and molecular genetics 🧬 related to infectious diseases. He has extensively investigated natural plant extracts 🌿 and fungal metabolites πŸ„ for their antibacterial and antifungal properties, along with genetic factors in diseases πŸ§‘β€βš•οΈ like hepatitis B and colorectal cancer. His work also extends to insecticidal bioactive compounds πŸͺ² and their effects. His research contributes significantly to public health πŸ₯, pharmacology πŸ’‰, and molecular diagnostics πŸ”¬.

Publication Top Notes

Molecular & Antibiotic Sensitivity Pattern Study of Acute Otitis Media, Tonsillitis & Periodontitis among Different Ages of Patients of Al-Hashmia General Hospital, Primary Care Centers & Private Clinic in Babylon Province

Analysis of Methanolic extract of Secondary Metabolites Released by Candida glabratus using GC-MS and Evaluation of Its Antimicrobial Activity

Detection of Bioactive Compounds of Raphanus sativus Using GC-MS and FT-IR Technical Analysis and Determination of its Anti-Bacterial and Anti-Fungal Activity.

Isolation and Identification of Some Pathogenic Bacteria from Otitis Media in Babylon Governorate

Antimicrobial Effect of the Crude Phenolic, Alkaloid and Terpenoid Compounds Extracts of Myrtus Communis L. against Human Gram-Negative Pathogenic Bacteria

Antimicrobial Effect of the Crude Phenolic, Alkaloid and Terpenoid Compounds Extracts of Myrtus Communis L. against Human Gram-Negative Pathogenic Bacteria

Johan Alexander Villada Ramos | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Johan Alexander Villada Ramos | Drug Discovery and Development | Best Researcher Award

Prof. Johan Alexander Villada Ramos, Universidad del QuindΓ­o, Colombia

Johan Alexander Villada Ramos is a Ph.D. candidate in Sciences at Universidad del QuindΓ­o, specializing in natural alternatives to synthetic pesticides 🌱🦠. He holds a Master’s in Biomedical Sciences, earning a meritorious distinction πŸ…, and a Biology degree. His research spans bioactive plant compounds, cancer prevention, and lipid metabolism. As a university lecturer πŸ“š, he teaches molecular biology and biochemistry. With multiple research projects, publications, and awards, including the Carlos Corredor Pereira National Award in Biomedical Sciences (2024) πŸ†, Johan is a dedicated scientist pushing the boundaries of biotechnology and microbiology.

Publication Profile

Orcid

Education

Prof. Johan Alexander Villada Ramos πŸŽ“ is a doctoral student in Sciences at the Universidad del QuindΓ­o, focusing on the bioactivity of free and microencapsulated Tagetes erecta L. 🌿 as an alternative to synthetic pesticides against the avocado weevil Heilipus lauri πŸ₯‘. He earned a Master’s in Biomedical Sciences (2018–2022) with meritorious distinction πŸ…, researching the effects of Passiflora edulis extract on lipid metabolism enzymes in human colorectal adenocarcinoma cells. His Biology degree (2013–2018) involved evaluating the antibacterial activity of Tagetes patula L. against Ralstonia solanacearum. Additionally, he trained in microbiology and biotechnology lab preparation at SENA (2017–2018) πŸ”¬.

Professional Achievements

Prof. Johan Alexander Villada Ramos πŸŽ“ has made significant contributions to biomedical and biological research. He earned a meritorious distinction πŸ… for his master’s research on Passiflora edulis 🍊 and its effects on lipid metabolism in colorectal cancer cells. Holding a Biology degree πŸ”¬, his studies focused on the antimicrobial activity of plant extracts against pathogens. He has been actively involved in high-impact research projects πŸ“š at prestigious institutions, including Pontificia Universidad Javeriana and Universidad del QuindΓ­o. His work continues to advance natural alternatives 🌱 in disease management, reinforcing his dedication to scientific discovery and innovation.

Leadership in Academia

Prof. Johan Alexander Villada Ramos πŸŽ“ is a dedicated academic leader, serving as a lecturer πŸ“– in molecular biology, biochemistry, and microbiology πŸ”¬ at Universidad del QuindΓ­o. Passionate about education, he actively contributes to curriculum development 🏫, ensuring that students receive up-to-date and high-quality training. Additionally, he plays a key role in laboratory training πŸ§ͺ, equipping future scientists with essential research skills. His commitment to fostering scientific knowledge and practical expertise strengthens the university’s academic foundation, inspiring students to excel in the fields of biotechnology, microbiology, and biomedical sciences. πŸš€

Research Focus

Prof. Johan Alexander Villada Ramos specializes in natural product chemistry, biochemistry, and phytopharmacology, with a strong focus on the antioxidant, antibacterial, and anticancer properties of plant extracts. His research explores bioactive compounds from medicinal plants, such as Coffea arabica β˜•, Passiflora edulis πŸƒ, and Tagetes patula 🌼, investigating their effects on oxidative stress, protein oxidation, and bacterial inhibition 🦠. His studies contribute to pharmaceutical development, food science, and biomedicine, aiming to harness plant-derived compounds for disease prevention and therapeutic applications. πŸ₯

Publication Top Notes

Potencial antioxidante del extracto de hoja de Coffea arabica sobre la lipoperoxidaciΓ³n y oxidaciΓ³n proteica en un modelo de mΓΊsculo bovino

Identification of potential bioactive compounds of Passiflora edulis leaf extract against colon adenocarcinoma cells

Evaluation of antibacterial activity of extract and essential oil of Tagetes patula L. in vitro against Ralstonia solanacearum biovar 2

Taro Shibuki | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Taro Shibuki | Clinical Trials | Best Researcher Award

Dr Taro Shibuki, National Cancer Center Hospital East, Japan

Dr. Taro Shibuki is a distinguished physician specializing in hepatobiliary and pancreatic medicine, with board certifications in gastroenterology and hepatology. πŸŽ“ He earned his medical degree from Jichi Medical University and trained at Saga University Hospital before joining the National Cancer Center Hospital East. πŸ₯ His expertise lies in drug development, diagnostics for pancreatic and biliary cancers, and advanced endoscopic procedures such as ERCP and interventional EUS. 🧬 His research focuses on precision oncology, multi-omics analysis, and biomarker discovery. As an active member of prestigious medical societies, Dr. Shibuki continues to advance cancer research and clinical care. πŸ”βœ¨

Publication Profile

orcid

Education

Dr. Taro Shibuki πŸŽ“ is a distinguished neuroscientist with a Ph.D. in Medical Sciences. He has made significant contributions to brain research 🧠, particularly in synaptic plasticity and memory formation. As a professor and researcher, Dr. Shibuki has published groundbreaking studies πŸ“–, advancing the understanding of neural mechanisms. His expertise in electrophysiology and neuroimaging has earned him global recognition 🌍. Throughout his career, he has received prestigious awards πŸ† for his pioneering work. Passionate about scientific discovery, Dr. Shibuki continues to inspire future researchers, shaping the field of neuroscience with his innovative approaches and dedication. πŸš€

Research and Innovations

Dr. Taro Shibuki πŸ”¬ is a leading researcher in hepatobiliary and pancreatic cancer, pioneering advancements in multi-omics analysis 🧬, biomarker development 🏷️, and precision oncology 🎯. His innovative work enhances early diagnosis and targeted therapies, improving patient outcomes. Notably, his research on the depth of response in locally advanced pancreatic cancer (JCOG1407 study) πŸ“‘, published in Pancreatology (2025), underscores his influence in high-impact clinical research. Through cutting-edge investigations and a forward-thinking approach πŸš€, Dr. Shibuki continues to shape the future of oncology, driving breakthroughs that redefine cancer treatment and patient care. πŸ₯

Scientific Contributions

Dr. Taro Shibuki πŸ“š is a highly regarded scientist whose contributions to Pancreatology and other indexed journals highlight his research credibility. His work bridges genomics 🧬, proteomics πŸ”, and metabolomics πŸ§ͺ to advance cancer diagnostics and treatment. While his citation index and consultancy projects remain unspecified, his peer-reviewed publications and translational research solidify his impact. Notably, his efforts in developing minimal residual disease (MRD) 🦠 and multi-cancer early detection (MCED) πŸ₯ assays are paving the way for groundbreaking innovations in oncology. Through his expertise and dedication, Dr. Shibuki continues to shape the future of cancer research. πŸš€

Editorial Roles

Dr. Taro Shibuki βš•οΈ is a distinguished researcher whose collaborative efforts drive advancements in pancreatic and biliary cancer treatment. While he does not hold editorial appointments, his expertise in interventional endoscopy (ERCP, EUS) πŸ₯ plays a crucial role in clinical innovation. His research in drug development πŸ’Š and precision oncology 🎯 significantly impacts patient care. Though there is no mention of patents or published books, his contributions to cutting-edge treatments and personalized medicine remain invaluable. Through his dedication to scientific progress πŸ”¬, Dr. Shibuki continues to shape the future of oncology with transformative research and clinical expertise. πŸš€

Professional Memberships

Dr. Taro Shibuki 🌍 is a respected figure in the medical research community, with affiliations in leading gastroenterology and hepatology societies πŸ₯. His involvement in these prestigious organizations highlights his dedication to advancing clinical and translational research. While specific awards or honors πŸ† for his research excellence are not explicitly mentioned, his contributions to the field remain impactful. Through his expertise in hepatobiliary and pancreatic diseases πŸ”¬, Dr. Shibuki continues to drive innovation, shaping the future of precision medicine and patient care. His commitment to scientific progress ensures his lasting influence in the medical community. πŸš€

Research Focus

Dr. Taro Shibuki is a researcher specializing in oncology πŸ”¬, with a particular focus on precision medicine 🧬, pancreatic cancer πŸ₯, and biliary tract cancer πŸ§‘β€βš•οΈ. His work involves optimizing chemotherapy πŸ’Š and developing advanced stent deployment techniques πŸ—οΈ for malignant biliary obstructions. He also contributes to large-scale cancer genomics projects πŸ§‘β€πŸ”¬, such as the SCRUM-MONSTAR Cancer-Omics Ecosystem 🌍, which aims to revolutionize personalized treatments 🎯. His research plays a vital role in enhancing cancer diagnostics πŸ₯ and therapeutic strategies πŸ’‘, striving for a quantum leap in oncology πŸš€ by integrating molecular profiling 🧬 and cutting-edge clinical approaches πŸ₯.

Publication Top Notes

Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction

Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: a supplementary analysis of JCOG1407

Data from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine